Dare Bioscience Inc
DARE
查看详细走势图
1.690USD
+0.010+0.60%
收盘 02/06, 16:00（美东）报价延迟15分钟
23.54M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.60%
5天
-6.63%
1月
-14.21%
6月
-17.16%
今年开始到现在
-12.44%
1年
-43.16%
查看详细走势图
TradingKey Dare Bioscience Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Dare Bioscience Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名105/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价10.75。中期看，股价处于平稳状态。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Dare Bioscience Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Dare Bioscience Inc亮点
亮点风险
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
业绩增长期
公司处于发展阶段，最新年度总收入9.78K美元
估值高估
公司最新PE估值-0.93，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值523.05K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.66
分析师目标
根据
4
位分析师
买入
评级
10.750
目标均价
+507.34%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Dare Bioscience Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Dare Bioscience Inc简介
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
公司代码DARE
公司Dare Bioscience Inc
CEOJohnson (Sabrina Martucci)
网址https://www.darebioscience.com/
相关品种
